NDC 52747-0621-30: Concept DHA Vitamin- Mineral Omega-3 Supplement 17.5 mg; 17.5 mg; 25 mg; 1 mg; 2 mg; 3 mg; 1.8 mg; 5 mg; 25 mg; 300 ug; 12.5 ug Capsule, Liquid Filled, Bottle of 30
This is a package of 30 capsules of Concept DHA Vitamin- Mineral Omega-3 Supplement 17.5 mg; 17.5 mg; 25 mg; 1 mg; 2 mg; 3 mg; 1.8 mg; 5 mg; 25 mg; 300 ug; 12.5 ug Capsule, Liquid Filled from U.S. Pharmaceutical Corporation, first listed with the FDA Jun 2009 and currently FDA-listed; retail pharmacies pay about $1.16 per capsule (NADAC). It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 52747-621-30 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 52747 labeler · 621 product · 30 package
- Package marketed since
- Jun 24, 2009
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 30 EA per package
- Barcode (UPC-A, from the NDC)
- 3 5274762130 8
- Medicaid fills, this package
- 845 prescriptions in the last four reported quarters
- FDA record last changed
- Nov 19, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 065127
- GCN: 21574
- GPI-14 (Medi-Span): 78512091000135
- HICL (First Databank): 036292
- AHFS class code: 20:04.04.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Concept DHA is an oral liquid-filled capsule containing a combination of vitamins, minerals, and omega-3 fatty acids. The product includes B vitamins (thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, and cyanocobalamin), vitamin C, and folic acid, which are typically used to support energy metabolism and general nutritional needs. It also contains iron, zinc, copper, and magnesium, minerals commonly included in prenatal and general wellness supplements. The formulation includes omega-3 fatty acids and DHA (docosahexaenoic acid), components typically found in nutritional supplements. This product is marketed without an approved FDA application.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $1.161 | $34.83 / 30 capsules |
| Medicaid paysCMS SDUD · 12 mo | $0.9917 | $29.75 / 30 capsules |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file · file of Nov 18, 2026
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 52747-0621-30 You're viewing this Main listing | 30 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC | 2009-06-24 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Concept DHA 17.5 mg/1; 17.5 mg/1; 25 mg/1; 1 mg/1; 2 mg/1; 3 mg/1; 1.8 mg/1; 5 mg/1; 25 mg/1; 300 ug/1; 12.5 ugthis 52747-0621-30 | U.S. | 30 capsules | $1.161 | — | Availability likely | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file · file of Nov 18, 2026
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII WZB9127XOA
A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
-
UNII 3NXW29V3WO
Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
-
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
-
UNII 2ZA36H0S2V
Beeswax is a natural wax produced by honeybees. In medicines, it works as a coating agent and thickener to control how fast the drug dissolves and improve the product's texture and appearance.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from U.S. Pharmaceutical Corporation labeler code 52747
- V-Bella BORIC ACID 3 [hp_X]/1 Suppository NDC 52747-155-03
- HYLAFEM BORICUM ACIDUM 3X 3 [hp_X]/1 Suppository NDC 52747-255-03
- Norel AD acetaminophen, chlorpheniramine maleate, and phenylephrine HCl 325 mg; 4 mg; 10 mg Tablet, Multilayer NDC 52747-475-70
- Concept OB Vitamin Mineral Supplement 42.5 mg; 42.5 mg; 210 mg; 1 mg; 5 mg; 5 mg; 20 mg; 7 mg; 25 mg; 300 ug; 10 ug Capsule NDC 52747-620-10
- Integra F Ferrous Fumarate and Polysacchride Iron Complex and Folic Acid 62.5 mg; 62.5 mg; 1 mg; 40 mg; 3 mg Capsule NDC 52747-711-30
- Integra Plus Ferrous Fumarate and Polysacchride Iron Vitamin Mineral Complex Supplement 62.5 mg; 62.5 mg; 1 mg; 210 mg; 20 mg; 5 mg; 5 mg; 5 mg; 25 mg; 300 ug Capsule NDC 52747-712-10
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS: Concept DHATM is a prescription prenatal vitamin-mineral preparation containing omega-3 fatty acid supplements designed to supply nutritional supplementation for women throughout pregnancy and during the postnatal period to lactating and non-lactating mothers. Concept DHATM may also be used to improve the nutritional status of women before conception.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION: Adults (persons over 12 years of age), one (1) capsule daily, between meals, or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.
⚠️ Warnings and Cautions ▾
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
WARNING: Ingestion of more than 3 grams of omega-3 fatty acids from fish oils per day may have potential antithrombotic effects, including an increased bleeding time and INR (international normalized ratio). DHA should be avoided in patients with inherited or acquired bleeding diatheses, including those taking anticoagulants. WARNING: Folic acid alone is improper therapy in the treatment for pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient.
PRECAUTIONS: General: Folic acid in doses above 0.1 mg - 0.4 mg daily may obscure pernicious anemia, in that hematological remission can occur while neurological manifestations remain progressive.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED: Concept DHA TM are red maroon opaque Vcaps ® capsules printed in white with "Concept DHA" on the cap "US" logo on the body. Packed in child-resistant cap and light resistant bottle of 30 capsules (52747-0621-30). The listed product number is not a National Drug Code.
Instead, US Pharmaceutical Corporation has assigned this product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and healthcare insurance computer systems. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Vcaps ® and the Vcaps ® Logo are trademarks used under license.
📋 Description ▾
DESCRIPTION: Each capsule contains: Ferrous Fumarate (Elemental Iron) . . . . . . . . . . 17.5 mg PolysaccharideIronComplex(ElementalIron).. 17.5mg (Equivalent to about 35 mg of elemental iron) Vitamin C (from ProAscorb C‡) . . . . . . . . . . . .
25 mg FolicAcid.............................. 1mg ThiamineMononitrate(B1) ................ 2mg Riboflavin(B2) ..........................
3mg Niacin (B3, from ProAscorb C‡) . . . . . . . . . . . . 1.8 mg d-CalciumPantothenate(B5)................ 5mg PyridoxineHCI(B6) ....................
25mg Biotin (B7) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300 mcg Cyanocobalamin(B12) ................ 12.5mcg Copper(asCopperSulfate)..................
2mg Magnesium(asMagnesiumSulfate) . . . . . . . . Zinc(asZincSulfate).................... Omega-3 Fatty Acids . . . . . . . . . ...........
(Derived from 310 mg Fish Oil) Docosahexaenoic Acid (DHA) . ........... Eicosapentaenoic Acid (EPA) . ........... . 5mg 10mg 200 mg156 mg 39 mg Clinical Studies: Because Ferrous Fumarate is an organic complex, it contains no free ions, either ferric or ferrous.
Polysaccharide Iron Complex is clinically non-toxic. Prior studies in rats demonstrated that Polysaccharide Iron Complex (PIC), administered as a single oral dose to Sprague Dawley rats did not produce evidence of toxicity at a dosage level of 5000 mg Iron/kg: (An Acute Oral Toxicity Study in Rats with Polysaccharide-Iron Complex. T.N.Merriman, M.
Aikman and R.E. Rush, Springborn Laboratories, Inc. Spencerville, Ohio Study No.
3340.1 March - April 1994). Other clinical studies had demonstrated that Polysaccharide Iron gives a good hematopoietic response with an almost complete absence of the side effects usually associated with oral iron therapy. Picinni and Ricciotti suggested in 1982, that "the therapeutic effectiveness of Polysaccharide Iron Complex when compared with iron fumarate in the treatment of iron deficiency anemia, appears to be as active as the iron fumarate and as well tolerated, however, it exerted a greater influence on the level of hemoglobin and on the number of red cells..." and that, "it has been exceptionally well tolerated by all patients" (Picinni, L.-Ricciotti, M.
1982. Therapeutic effectiveness of an iron-polysaccharide complex in comparison with iron fumarate in the treatment of iron deficiency anemias): PANMINERVA MEDICA-EUROPA MEDICA, Vol. 24, No.
3, pp. 213-220 (July - September 1982). As mentioned above, the patented source of iron used in Concept DHATM (Ferrous Fumarate and Polysaccharide Iron Complex) provides a high level of elemental iron with a low incidence of gastric distress.
CONCLUSION: Based on the results of this study, the oral combination of Ferrous Fumarate and Polysaccharide Iron Complex was better tolerated and safer than the oral administration of Ferrous Fumarate alone. The conclusion of this research stated, that the addition of PIC to Ferrous Fumarate surprisingly allows the same concentration of Ferrous Fumarate to be better tolerated than the Ferrous Fumarate alone. INDICATIONS: Concept DHATM is a prescription prenatal vitamin-mineral preparation containing omega-3 fatty acid supplements designed to supply nutritional supplementation for women throughout pregnancy and during the postnatal period to lactating and non-lactating mothers.
Concept DHATM may also be used to improve the nutritional status of women before conception. WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children.
In case of accidental overdose, call a doctor or poison control center immediately. WARNING: Ingestion of more than 3 grams of omega-3 fatty acids from fish oils per day may have potential antithrombotic effects, including an increased bleeding time and INR (international normalized ratio). DHA should be avoided in patients with inherited or acquired bleeding diatheses, including those taking anticoagulants.
WAR… [Excerpted — this section continues on DailyMed.]
🔬 Clinical Studies ▾
Clinical Studies: Because Ferrous Fumarate is an organic complex, it contains no free ions, either ferric or ferrous. Polysaccharide Iron Complex is clinically non-toxic. Prior studies in rats demonstrated that Polysaccharide Iron Complex (PIC), administered as a single oral dose to Sprague Dawley rats did not produce evidence of toxicity at a dosage level of 5000 mg Iron/kg: (An Acute Oral Toxicity Study in Rats with Polysaccharide-Iron Complex.
T.N.Merriman, M. Aikman and R.E. Rush, Springborn Laboratories, Inc.
Spencerville, Ohio Study No. 3340.1 March - April 1994). Other clinical studies had demonstrated that Polysaccharide Iron gives a good hematopoietic response with an almost complete absence of the side effects usually associated with oral iron therapy.
Picinni and Ricciotti suggested in 1982, that "the therapeutic effectiveness of Polysaccharide Iron Complex when compared with iron fumarate in the treatment of iron deficiency anemia, appears to be as active as the iron fumarate and as well tolerated, however, it exerted a greater influence on the level of hemoglobin and on the number of red cells..." and that, "it has been exceptionally well tolerated by all patients" (Picinni, L.-Ricciotti, M. 1982. Therapeutic effectiveness of an iron-polysaccharide complex in comparison with iron fumarate in the treatment of iron deficiency anemias): PANMINERVA MEDICA-EUROPA MEDICA, Vol.
24, No. 3, pp. 213-220 (July - September 1982).
As mentioned above, the patented source of iron used in Concept DHATM (Ferrous Fumarate and Polysaccharide Iron Complex) provides a high level of elemental iron with a low incidence of gastric distress. CONCLUSION: Based on the results of this study, the oral combination of Ferrous Fumarate and Polysaccharide Iron Complex was better tolerated and safer than the oral administration of Ferrous Fumarate alone. The conclusion of this research stated, that the addition of PIC to Ferrous Fumarate surprisingly allows the same concentration of Ferrous Fumarate to be better tolerated than the Ferrous Fumarate alone.
📄 Package Label / Principal Display Panel ▾
Packaging Concept DHA
Medicaid utilization & spend
Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |